Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson INVOKANA / INVOKAMET [reported separately through by Year
INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide reported growth YoY (%) (%)
Johnson & Johnson INVOKANA / INVOKAMET [reported separately through: -20.4% in FY2022, up 8.9 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2022 figure comes from
“|| WW | 448 | 563 | (20.4) | (17.2) | (3.2)”
Source: Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Jan 1, 2023 | -20.4% | +8.9 pts | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
| FY2021 | Jan 2, 2022 | -29.3% | -37.5 pts | Form 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗ |
| FY2020 | Jan 3, 2021 | 8.2% | +24.7 pts | Form 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗ |
| FY2019 | Dec 29, 2019 | -16.5% | +4.2 pts | Form 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗ |
| FY2018 | Dec 30, 2018 | -20.7% | +0.3 pts | Form 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗ |
| FY2017 | Dec 31, 2017 | -21.0% | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson INVOKANA / INVOKAMET [reported separately through (%), annual FY2017–FY2022 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-invokana-rep-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.